The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Martin R. Farlow

Department of Neurology

Indiana University School of Medicine




Name/email consistency: high



  • Department of Neurology, Indiana University School of Medicine, Indianapolis, USA. 1998 - 2011


  1. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. Farlow, M.R., Grossberg, G.T., Meng, X., Olin, J., Somogyi, M. Int. J. Geriatr. Psychiatry (2011) [Pubmed]
  2. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. Farlow, M., Veloso, F., Moline, M., Yardley, J., Brand-Schieber, E., Bibbiani, F., Zou, H., Hsu, T., Satlin, A. BMC. Neurol (2011) [Pubmed]
  3. Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? Farlow, M.R. Alzheimers. Res. Ther (2010) [Pubmed]
  4. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Farlow, M.R., Alva, G., Meng, X., Olin, J.T. Curr. Med. Res. Opin (2010) [Pubmed]
  5. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Farlow, M.R., Salloway, S., Tariot, P.N., Yardley, J., Moline, M.L., Wang, Q., Brand-Schieber, E., Zou, H., Hsu, T., Satlin, A. Clin. Ther (2010) [Pubmed]
  6. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. Farlow, M.R., Cummings, J.L., Olin, J.T., Meng, X. Am. J. Alzheimers. Dis. Other. Demen (2010) [Pubmed]
  7. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Farlow, M.R., Grossberg, G., Gauthier, S., Meng, X., Olin, J.T. Curr. Med. Res. Opin (2010) [Pubmed]
  8. Treatment of mild cognitive impairment (MCI). Farlow, M.R. Curr. Alzheimer. Res (2009) [Pubmed]
  9. A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Farlow, M.R., Cummings, J. Dement. Geriatr. Cogn. Disord (2008) [Pubmed]
  10. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Farlow, M.R., Miller, M.L., Pejovic, V. Dement. Geriatr. Cogn. Disord (2008) [Pubmed]
  11. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Farlow, M.R., Graham, S.M., Alva, G. Drug. Saf (2008) [Pubmed]
  12. Effective pharmacologic management of Alzheimer's disease. Farlow, M.R., Cummings, J.L. Am. J. Med. (2007) [Pubmed]
  13. Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Farlow, M.R. Mayo Clin. Proc. (2006) [Pubmed]
  14. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. Farlow, M.R., Lilly, M.L. BMC. Geriatr (2005) [Pubmed]
  15. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Farlow, M.R., Small, G.W., Quarg, P., Krause, A. Dement. Geriatr. Cogn. Disord (2005) [Pubmed]
  16. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers. Farlow, M., Lane, R., Kudaravalli, S., He, Y. Pharmacogenomics J. (2004) [Pubmed]
  17. Impact of APOE in mild cognitive impairment. Farlow, M.R., He, Y., Tekin, S., Xu, J., Lane, R., Charles, H.C. Neurology (2004) [Pubmed]
  18. Utilizing combination therapy in the treatment of Alzheimer's disease. Farlow, M.R. Expert. Rev. Neurother (2004) [Pubmed]
  19. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow, M., Potkin, S., Koumaras, B., Veach, J., Mirski, D. Arch. Neurol. (2003) [Pubmed]
  20. Update on rivastigmine. Farlow, M.R. Neurologist (2003) [Pubmed]
  21. Clinical pharmacokinetics of galantamine. Farlow, M.R. Clin. Pharmacokinet (2003) [Pubmed]
  22. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Farlow, M. Int. Psychogeriatr (2002) [Pubmed]
  23. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Farlow, M.R., Hake, A., Messina, J., Hartman, R., Veach, J., Anand, R. Arch. Neurol. (2001) [Pubmed]
  24. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Farlow, M.R. Clin. Ther (2001) [Pubmed]
  25. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Farlow, M.R., Cyrus, P.A. Dement. Geriatr. Cogn. Disord (2000) [Pubmed]
  26. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Farlow, M., Anand, R., Messina, J., Hartman, R., Veach, J. Eur. Neurol. (2000) [Pubmed]
  27. Etiology and pathogenesis of Alzheimer's disease. Farlow, M.R. Am. J. Health. Syst. Pharm (1998) [Pubmed]
WikiGenes - Universities